Drugs and patents in ATC class D08AH

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
INDIUM IN 111 OXYQUINOLINE	indium in-111 oxyquinoline
NYSTAFORM	clioquinol; nystatin
>Tradename	>Generic Name

Last updated: August 1, 2026

ATC Class D08AH covers quinoline derivatives used primarily as topical antiseptics and anti-infective agents. The class is commercially narrow and dominated by legacy molecules, principally clioquinol and iodoquinol. Their core compound patents and early formulation patents have expired. Current commercial value is concentrated in generic topical creams, combination products, hospital supply, compounding, and niche dermatology uses rather than protected branded products.

The main market risks are regulatory discontinuation, limited manufacturing capacity, product-specific formulation know-how, and low-volume economics. Patent-based barriers to U.S. generic entry are generally weak. No biosimilar pathway applies because D08AH products are small-molecule drugs.

What drugs are included in ATC Class D08AH?

ATC D08AH is the quinoline-derivative subgroup within topical antiseptics. The principal active ingredients are clioquinol and iodoquinol.

Active ingredient	Chemical identity	Common topical use	Typical dosage forms	U.S. commercial position
Clioquinol	5-chloro-7-iodo-8-quinolinol	Antiseptic and antifungal treatment, often in combination products	Cream, ointment, lotion	Legacy and limited-market product; availability varies
Iodoquinol	5,7-diiodo-8-quinolinol	Topical treatment of fungal and inflammatory dermatoses, usually with corticosteroids	Cream, ointment	Generic and combination-product market
Iodochlorhydroxyquin	Historical synonym associated with clioquinol	Topical antimicrobial use	Cream and ointment	Mostly legacy nomenclature

Clioquinol and iodoquinol are unrelated to hydroxychloroquine, chloroquine, quinine, and other systemic quinoline drugs. Those products fall into different therapeutic and ATC categories.

The World Health Organization places D08AH within dermatological antiseptics and disinfectants, not within systemic anti-infective or antimalarial categories (World Health Organization, 2024).

What products and indications drive the D08AH market?

The market is driven by topical products, particularly low-cost creams containing a quinoline derivative alone or combined with a corticosteroid.

Clioquinol products

Clioquinol has historically been marketed for superficial fungal infections, bacterial skin infections, infected eczema, and other inflammatory dermatoses. Commercial products have included clioquinol alone and combinations with hydrocortisone or other topical corticosteroids.

Its historical use was affected by safety concerns associated with systemic exposure and prolonged use. The drug was withdrawn from some markets for oral use after reports of subacute myelo-optic neuropathy, commonly called SMON. That history reduced the commercial role of clioquinol but did not eliminate topical use in all jurisdictions.

Iodoquinol products

Iodoquinol is generally sold in dermatology products containing a corticosteroid, most commonly hydrocortisone. U.S. labeling for iodoquinol and hydrocortisone products identifies use in steroid-responsive dermatoses with secondary infection or suspected infection (U.S. Food and Drug Administration, 2023a).

The combination product has greater commercial relevance than iodoquinol monotherapy because the corticosteroid addresses inflammation while iodoquinol provides antibacterial and antifungal activity. This combination also creates the principal opportunity for formulation differentiation.

How large is the market for quinoline-derivative antiseptics?

D08AH is a small, mature, fragmented market. Public sources do not provide a reliable global sales total for the ATC class because sales are reported by product, country, formulation, and combination rather than by the ATC subgroup.

The commercial profile is characterized by:

Market factor	D08AH impact
Product maturity	Active ingredients have been used for decades
Pricing	Generic and generally low to moderate
Prescribing	Limited to dermatology, primary care, and selected institutional settings
Competition	Multiple topical anti-infective and corticosteroid alternatives
Reimbursement	Dependent on country and product status
Patient volume	Niche relative to azole antifungals and topical antibiotics
Switching risk	High because physicians can substitute other topical agents
Supply risk	More important than patent risk in small markets

Competitive products include clotrimazole, miconazole, ketoconazole, nystatin, mupirocin, fusidic acid, chlorquinaldol, and corticosteroid-antimicrobial combinations. Many alternatives have stronger current brand recognition, broader clinical familiarity, or larger distribution networks.

Revenue exposure for originators is therefore modest in absolute terms. The highest commercial sensitivity is likely to occur at the individual product level, particularly where a company has an exclusive distributor, a hospital contract, or a differentiated combination formulation.

What patents protect clioquinol and iodoquinol?

The foundational composition-of-matter patents for clioquinol and iodoquinol are expired. Both compounds were developed and commercialized before the modern U.S. patent term framework applied to most pharmaceutical products.

Core compound protection

Patent category	Current status
Clioquinol composition patents	Expired
Iodoquinol composition patents	Expired
Basic topical antiseptic use patents	Expired or no longer commercially relevant
Early cream and ointment patents	Expired
Historical combination patents	Generally expired
Modern formulation patents	Potentially relevant only if directed to a specific technical improvement

The relevant patent question is not whether a molecule has a historical patent estate. It is whether a current product relies on an unexpired, enforceable claim covering its exact formulation, dosage form, method of use, or manufacturing process.

For legacy D08AH compounds, the answer is usually no at the active-ingredient level. Any remaining patent risk would arise from a later patent directed to a narrow formulation, a particular excipient system, a delivery technology, or a new therapeutic use.

When do clioquinol and iodoquinol lose exclusivity?

Clioquinol and iodoquinol lost core exclusivity decades ago. They have no meaningful remaining composition-of-matter exclusivity in the United States or major European markets.

Exclusivity timeline

Exclusivity type	Clioquinol	Iodoquinol
Composition-of-matter protection	Expired	Expired
New chemical entity exclusivity	Not available for current products	Not available for current products
U.S. orphan exclusivity	No generally relevant current protection	No generally relevant current protection
Pediatric exclusivity	No known current class-wide protection	No known current class-wide protection
Biosimilar exclusivity	Not applicable	Not applicable
Current patent-based exclusivity	Product-specific only	Product-specific only

FDA regulatory exclusivity attaches to an approved product and its statutory pathway. It does not recreate exclusivity for an old active ingredient merely because a manufacturer obtains a new approval for a topical formulation.

What is the Orange Book status of D08AH products?

The Orange Book status is product-specific. D08AH does not have a single class-wide Orange Book listing.

U.S. products containing iodoquinol and hydrocortisone have historically been marketed as prescription topical combinations. Listed patents, if any, must be assessed against the specific product and approval holder. Many legacy products have limited or changing commercial status, including discontinued products, reformulations, and products marketed under abbreviated or private-label arrangements.

The key Orange Book diligence questions are:

Whether the reference product has an active approved application.
Whether the specific strength and dosage form remain marketed.
Whether any patent is listed for that reference product.
Whether the patent covers the drug substance, formulation, or method of use.
Whether the product is eligible for an ANDA reference pathway.

A generic applicant should not assume that the absence of a current brand presence eliminates regulatory work. FDA may require a suitability determination, a new drug application, or another pathway if the proposed product differs materially from an eligible reference product in formulation, dosage form, or active-ingredient status (U.S. Food and Drug Administration, 2023b).

Are there Paragraph IV challenges for clioquinol or iodoquinol?

Paragraph IV litigation risk is low. The principal reasons are the age of the active ingredients, the absence of meaningful composition patents, and the limited revenue available to support litigation.

A Paragraph IV certification would matter only if an ANDA applicant identified a listed patent that was allegedly invalid, unenforceable, or not infringed. For legacy topical products, the more likely regulatory routes are:

Paragraph III certification if a listed patent remains and is accepted as valid until expiry.
Paragraph IV certification for a narrow formulation or method patent.
A certification that no relevant patent is listed.
A 505(b)(2) application where the product relies partly on published literature or a prior approved product but differs in formulation, indication, or clinical use.

The probability of a meaningful Hatch-Waxman case is materially lower than for high-value branded dermatology products such as topical retinoids, corticosteroids, or novel anti-infective combinations.

What formulation patents could protect D08AH products?

Formulation patents are the most plausible source of residual protection. They would need to claim a technically specific and commercially relevant feature, such as:

Improved stability of an iodine-containing quinoline derivative.
Reduced discoloration or odor.
Enhanced skin penetration.
A controlled-release topical matrix.
A low-irritation vehicle.
A particular oil-in-water or water-in-oil emulsion.
A combination with a corticosteroid at defined ratios.
Preservation systems that maintain potency.
Packaging that limits light, moisture, or oxidation.
A gel, foam, spray, or transdermal delivery system.

A formulation patent does not automatically block a conventional generic cream. Its practical value depends on claim scope and whether the protected feature is necessary for the reference product's performance.

Formulation design-around risk

Patent feature	Generic design-around potential
Specific excipient concentration	Usually high
Defined emulsion phase ratio	High to moderate
Broad combination claim	Moderate
Narrow particle-size or delivery claim	Moderate
Stability claim tied to a unique vehicle	Moderate
Device-dependent delivery system	Depends on device architecture
Manufacturing-process claim	Often high if an alternative process is available

For a new entrant, formulation development is likely to create greater technical differentiation than patent protection. A product with a familiar cream base can often be developed without reproducing a protected proprietary vehicle.

What method-of-use patents protect quinoline derivatives?

Method-of-use patents are unlikely to provide broad protection for traditional topical antiseptic indications because the main uses have long been described in medical and patent literature.

Potentially protectable uses could include:

A defined inflammatory skin condition.
A particular treatment duration.
Use in a specified patient population.
Treatment of a resistant organism.
A combination regimen with a corticosteroid or immunomodulator.
Use in a wound-care or device-associated setting.

The commercial value of such patents is limited if physicians already use competing anti-infectives for the same condition. A method patent may also be difficult to enforce when the product label does not expressly include the patented use.

How strong is the D08AH patent estate?

The class-wide patent estate is weak.

Patent-strength factor	Assessment
Active-ingredient patents	Very weak; expired
Broad topical-use patents	Very weak
Combination patents	Usually weak unless recently developed
Formulation patents	Potentially moderate but narrow
Manufacturing patents	Potentially relevant to suppliers, not usually market-blocking
Orange Book blocking patents	Product-specific and limited
Litigation leverage	Low
Generic entry exposure	High

Patent strength should be evaluated at the product level, not the ATC-class level. A company with a modern delivery system could possess meaningful rights even though the underlying molecule is unprotected. That protection would not extend to all clioquinol or iodoquinol products.

Which companies are challenging D08AH products?

The market does not have a consistent branded challenger structure. Competition is primarily among generic manufacturers, contract manufacturers, private-label suppliers, and regional dermatology companies.

Potential participants include:

Generic topical manufacturers with ANDA or national-market approvals.
Companies supplying iodoquinol-hydrocortisone combinations.
Dermatology companies acquiring legacy products.
Contract manufacturers producing creams and ointments for regional brands.
Compounding pharmacies where commercial supply is limited.

The absence of prominent public Paragraph IV litigation indicates that competition is more likely to occur through price, availability, formulation execution, and distribution than through patent challenges.

What FDA regulatory issues affect generic entry?

FDA approval depends on the product's regulatory status, dosage form, active ingredients, and reference-product availability.

U.S. regulatory considerations

A prospective entrant must address:

Whether the active ingredient is eligible for an ANDA pathway.
Whether an appropriate reference listed drug exists.
Whether the product is a prescription or nonprescription drug.
Whether the combination has the same active ingredients and strengths as the reference.
Whether the proposed vehicle is sufficiently comparable.
Microbiological quality and preservative effectiveness.
Assay, impurity, and stability specifications.
Dermal irritation and sensitization.
Manufacturing controls for iodine-containing materials.
Labeling limitations relating to duration and extent of use.

Topical products can present bioequivalence problems even when the active ingredients are old. FDA may require comparative clinical endpoint studies, in vitro release testing, or other evidence depending on the product-specific guidance and reference product.

Does biosimilar risk apply to D08AH?

No. Biosimilar risk does not apply to clioquinol or iodoquinol because they are chemically synthesized small molecules, not biologic products.

The relevant competitive threat is generic substitution. Generic entry can occur through an ANDA or, in some circumstances, through a 505(b)(2) application. The timing depends on reference-product status, patent listings, regulatory exclusivity, and formulation equivalence.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are operational rather than foundational patent barriers.

Manufacturing risks

Iodinated quinoline derivatives may create challenges involving:

Raw-material sourcing.
Halogenated intermediate control.
Impurity profiles.
Color and odor consistency.
Light sensitivity.
Uniform dispersion in semisolid bases.
Batch-to-batch rheology.
Preservative compatibility.
Tube and container interaction.
Regional hazardous-material and waste requirements.

A supplier with a qualified process, stable raw-material chain, and validated topical manufacturing line may have a practical advantage over a nominally patent-free entrant.

Manufacturing-process patents could protect a particular purification or crystallization method. These patents would generally be easier to design around than a composition-of-matter patent and may not prevent market entry if an alternative process produces compliant material.

How does D08AH compare with competing topical anti-infective classes?

Class	Representative drugs	Patent position	Market strength
Quinoline derivatives	Clioquinol, iodoquinol	Mature and largely unprotected	Niche
Imidazole antifungals	Clotrimazole, miconazole, ketoconazole	Largely generic	Broad
Polyene antifungals	Nystatin	Generic, strong clinical familiarity	Broad
Topical antibiotics	Mupirocin, fusidic acid	Mupirocin largely mature; product-specific formulations may differ	Broad to moderate
Corticosteroid combinations	Hydrocortisone combinations	Mostly generic, formulation-dependent	Broad
New dermatology agents	Novel nonsteroidal anti-inflammatory and antimicrobial products	May retain active patents	Higher value

D08AH products compete on availability and prescribing familiarity, not on a differentiated mechanism or modern patent estate. A generic iodoquinol combination may still obtain commercial value in markets where physicians prefer established combination therapy or where competing products face supply shortages.

What generic launch scenarios exist for D08AH products?

Conventional generic launch

The most likely scenario is a standard topical generic that matches the reference product's active ingredients, strength, dosage form, and labeling. Patent risk is low, while bioequivalence and manufacturing validation remain central.

Limited-market launch

A manufacturer may target selected wholesalers, dermatology practices, hospitals, or shortage markets. This approach limits commercial investment but can support acceptable margins in a small category.

Reformulated product

A new cream, gel, or lotion may be submitted through a 505(b)(2) strategy if it offers a materially different vehicle, delivery profile, or indication. This route can create regulatory and formulation differentiation but may require additional clinical or comparative evidence.

Combination-product launch

A company may compete through a quinoline derivative combined with a corticosteroid or another topical agent. The combination can improve prescribing relevance but may create additional regulatory requirements and formulation complexity.

What is the geographic patent coverage for D08AH?

Geographic patent coverage is limited because the principal compounds are old. Any residual rights would be jurisdiction-specific and concentrated in later formulations, delivery systems, or new uses.

Region	Core molecule status	Main commercial issue
United States	Core patents expired	Reference-product and formulation pathway
European Union	Core patents expired	National authorization and market availability
Japan	Core patents expired	Product-specific approval and local distribution
China	Core patents expired	Local registration, supply, and generic competition
Latin America	Core patents generally expired	National registration and procurement
Emerging markets	Generally no core patent barrier	Manufacturing quality and channel access

A global launch still requires country-by-country review of approved indications, prescription status, local trademarks, formulation registrations, and pharmacovigilance obligations.

What litigation and settlement agreements affect D08AH?

There is no widely recognized, class-wide patent litigation campaign comparable with litigation surrounding high-revenue dermatology or specialty medicines. Settlement agreements are therefore unlikely to be a major determinant of generic entry timing.

Any relevant dispute would most likely involve:

A formulation patent.
Trade dress or trademark rights.
Product ownership or licensing.
Manufacturing supply.
Labeling or regulatory exclusivity.
Quality, shortage, or distribution issues.

The commercial consequence of a dispute would generally be limited to a specific product or market rather than the entire D08AH class.

Key Takeaways

ATC D08AH is a small topical antiseptic class centered on clioquinol and iodoquinol.
Core compound patents and historical use patents have expired.
Current patent risk is concentrated in narrow formulations, delivery systems, manufacturing processes, and new methods of use.
U.S. Orange Book and Paragraph IV risk is product-specific and generally low.
Generic substitution, not biosimilar competition, is the relevant market threat.
Commercial performance depends more on manufacturing reliability, regulatory pathway, distribution, and formulation quality than on patent exclusivity.
The strongest launch opportunity is a compliant, reliable topical generic or a differentiated combination product aimed at a defined regional or institutional market.

FAQs on D08AH Quinoline Derivatives

Is clioquinol still patent protected?

No. The core clioquinol molecule is not protected by current composition-of-matter exclusivity. A later formulation or delivery patent could still apply to a specific product.

Is iodoquinol available as a generic?

Yes. Iodoquinol is generally available through generic or legacy combination products, although commercial availability differs by jurisdiction and product strength.

Can a company file an ANDA for iodoquinol cream?

Potentially. The applicant must identify an eligible reference product and demonstrate the required pharmaceutical equivalence, bioequivalence, quality, and labeling compliance.

Are clioquinol and iodoquinol antifungals or antiseptics?

They have both antiseptic and antifungal activity in topical use. Their ATC classification places them under dermatological antiseptics and disinfectants.

What is the main investment risk in D08AH products?

The main risk is low market scale combined with supply and regulatory complexity. Patent litigation risk is generally secondary to manufacturing economics, product availability, and competition from established topical anti-infectives.

References

U.S. Food and Drug Administration. (2023a). Iodoquinol and hydrocortisone cream prescribing information. FDA labeling database.
U.S. Food and Drug Administration. (2023b). Approved drug products with therapeutic equivalence evaluations. 43rd ed. FDA.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: D08AH quinoline derivatives. WHO.
DailyMed. (2024). Iodoquinol and hydrocortisone topical product labeling. U.S. National Library of Medicine.
U.S. Food and Drug Administration. (2024). Draft guidance on topical dermatologic drug products submitted in abbreviated new drug applications. FDA.